Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Want to cut your energy bills? Here’s how five experts are doing it 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
SEATTLE and SOUTH SAN FRANCISCO, Calif., June 01, 2017 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference in New York on Wednesday, June 7, 2017 at 8 a.m. ET.
A live webcast of the presentation will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm. After the live webcast, an archive of the presentation will be available on the company website for 30 days.
About Immune Design
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the primary foci of Immune Design's ongoing immuno-oncology clinical programs, are products of its two synergistic discovery platforms, ZVex® and GLAAS®. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.
Media Contact Julie Rathbun Rathbun Communications [email protected] 206-769-9219 Investor Contact Shari Annes Annes Associates [email protected] 650-888-0902
